Petrochemical Group Co., Ltd. announced that Mingfu® (an injectable recombinant TNK tissue type cellulase activator) developed by Mingfu Pharmaceutical (Guangzhou) Co., Ltd. has been approved by the China National Drug Administration for the treatment of thrombus therapy in patients with acute ischemic stroke. This is the second indication for the product to be approved in China and the first of its kind to receive this approval. The product's approval is based on efficacy and safety results from Phase III clinical trials, and the results of the study have been published in the journal Willow Knife. With a longer half-life and stronger fibroprotein specificity, Mingfu® provides rapid single pellet-type intravenous injection, showing significant clinical application advantages. The Chairman of Petrochemical Group, Tung Chen, made this announcement on February 5, 2024.

Petrochemical Group Co., Ltd. announced that Mingfu® (an injectable recombinant TNK tissue type cellulase activator) developed by Mingfu Pharmaceutical (Guangzhou) Co., Ltd. has been approved by the China National Drug Administration for the treatment of thrombus therapy in patients with acute ischemic stroke. This is the second indication for the product to be approved in China and the first of its kind to receive this approval. The product's approval is based on efficacy and safety results from Phase III clinical trials, and the results of the study have been published in the journal Willow Knife. With a longer half-life and stronger fibroprotein specificity, Mingfu® provides rapid single pellet-type intravenous injection, showing significant clinical application advantages. The Chairman of Petrochemical Group, Tung Chen, made this announcement on February 5, 2024.